Journal of Neural Transmission,
Journal Year:
2023,
Volume and Issue:
130(11), P. 1349 - 1358
Published: Sept. 6, 2023
Abstract
Advanced
Parkinson’s
disease
is
characterized
by
periods
of
poor
mobility,
dyskinesia
and
progressive
decline
in
functional
independence
the
affected
person
despite
manipulation
levodopa
doses
introduction
supplemental
therapies
such
as
catechol-O-methyl
transferase
inhibitors,
monoamine
oxidase-B
inhibitors
dopamine
agonists.
The
implementation
drug
delivery
systems
allows
to
bypass
problems
related
irregular
often
unpredictable
intestinal
absorption
oral
levodopa,
which
significantly
affects
its
bioavailability
contributes
development
persistence
motor
complications.
Subcutaneous
apomorphine
levodopa/carbidopa
jejunal
infusion
have
been
available
for
many
years
their
efficacy
confirmed
randomized
studies
long-term
experience
centers
worldwide.
Recently,
a
new
formulation
gel
that
includes
inhibitor
Entacapone
has
introduced
market.
use
entacapone
reduce
total
daily
dose
administered
levodopa.
Two
different
soluble
formulations
(ND0612
ABBV-951)
completed
clinical
development,
both
can
ensure
subcutaneous
portable
pump
system.
ABBV-951
uses
foslevodopa/foscarbidopa
formulation,
prodrugs
improve
tolerability.
Both
provide
effective
improvement
complications
are
likely
expand
therapeutic
options
advanced
patients.
Future
efforts
should
focus
on
earlier
detection
patients
who
candidates
device-aided
therapies,
increasing
appropriate
referral
broadening
availability
these
treatments
globally.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: July 2, 2024
Abstract
Ferroptosis
is
an
iron-dependent
cell
death
form
characterized
by
reactive
oxygen
species
(ROS)
overgeneration
and
lipid
peroxidation.
Myricetin,
a
flavonoid
that
exists
in
numerous
plants,
exhibits
potent
antioxidant
capacity.
Given
iron
accumulation
ROS-provoked
dopaminergic
neuron
are
the
two
main
pathological
hallmarks
of
Parkinson’s
disease
(PD),
we
aimed
to
investigate
whether
myricetin
decreases
neuronal
through
suppressing
ferroptosis.
The
PD
models
were
established
intraperitoneally
injecting
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)
into
rats
treating
SH-SY5Y
cells
with
1-methyl-4-phenylpyridinium
(MPP
+
),
respectively.
was
identified
assessing
levels
Fe
2+
,
ROS,
malondialdehyde
(MDA),
glutathione
(GSH).
results
demonstrated
treatment
effectively
mitigated
MPTP-triggered
motor
impairment,
dopamine
death,
α-synuclein
(α-Syn)
models.
Myricetin
also
alleviated
MPTP-induced
ferroptosis,
as
evidenced
decreased
MDA
increased
GSH
substantia
nigra
(SN)
serum
All
these
changes
reversed
erastin,
ferroptosis
activator.
In
vitro,
restored
viability
MPP
-induced
Mechanistically,
accelerated
nuclear
translocation
factor
E2-related
2
(Nrf2)
subsequent
peroxidase
4
(Gpx4)
expression
-treated
cells,
critical
inhibitors
Collectively,
data
demonstrate
may
be
potential
agent
for
decreasing
inhibiting
PD.
Movement Disorders Clinical Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 25, 2025
Levodopa-entacapone-carbidopa
intestinal
gel
(LECIG)
was
introduced
in
2018
as
a
device-aided
therapy
for
advanced
Parkinson's
disease
(PD).
The
ELEGANCE
study
(NCT05043103)
is
gathering
real-world
data
on
long-term
efficacy,
safety
and
patient-reported
outcomes
with
LECIG
from
13
European
countries.
This
article
reports
the
planned
interim
analysis.
enrolled
patients
prescribed
part
of
routine
clinical
care.
We
evaluated
at
V1
before
starting
treatment
(in
seven
were
obtained
retrospectively),
thereafter
V2
(3-6
months)
or
V3
(6-12
months).
analysis
includes
167
37
centers.
Three
this
set
(1.8%)
discontinued
study.
Mean
(±SD)
daily
OFF-time
hours
(MDS-UPDRS
IV
item
4.3)
substantially
reduced
by
3.47
±
3.56
h
(baseline:
5.15
3.05;
P
<
0.0001).
Similarly,
MDS-UPDRS
total
scores
4.24
4.08
10.77
3.83);
(P
=
0.0001)
II
3.63
7.76
20.65
8.17;
0.0004).
PDSS-2
sustainably
improved
(reduction
7.38
10.72
[baseline:
25.21
10.62];
0.0001),
PDQ-8
summary
index
score
indicating
an
improvement
quality
life
(QoL)
13.3
19.05
46.34
20.09];
For
all
parameters
improvements
maintained
V3.
Patient-reported
satisfaction
pump
high.
Most
adverse
events
related
to
procedure
device.
Routine
use
up
12
months
provided
sustained
control
motor
symptoms,
well
tolerated
positive
impact
QoL
high
patient
satisfaction.
Expert Opinion on Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
24(15), P. 1693 - 1701
Published: July 26, 2023
ABSTRACTIntroduction
Behavioural
symptoms
are
common
manifestations
of
Parkinson’s
disease
and
include
depression,
anxiety,
impulse
control
disorders,
hallucinations,
psychosis,
cognitive
dysfunction.
They
remain
inadequately
addressed
in
many
patients
despite
their
relevance
for
quality
life
disability.
This
applies
also
to
disorders
where
the
most
approach
recent
literature
is
refrain
from
using
dopamine
agonists
without
consideration
about
potential
benefit
on
motor
complications.Areas
covered
We
conducted
a
narrative
review
searching
articles
behavioral
Parkinson
selected
those
which
included
involved
neurotransmitters
such
as
dopamine,
noradrenaline,
serotonin,
acetylcholine.
specifically
focused
our
search
open-label
randomized
double-blind
studies
biomarkers
could
best
characterize
these
clinical
manifestations.Expert
opinion
Management
behavioural
lacks
clear
guidelines
standardized
protocols
beside
general
suggestions
dose
adjustments
replacement
therapy
use
antidepressants
or
antipsychotic
drugs
with
little
patients’
age,
sex,
comorbidities,
status.
suggest
pragmatic
includes
education
affected
caring
people,
dealing
complex
cases
by
experienced
multidisciplinary
teams,
therapy,
psychological
counselling
complement
drug
treatment.KEYWORDS:
Parkinson's
DiseaseDepressionNeuropsychiatric
symptomsNeuropsychiatric
SymptomsAnxiety
Article
highlights
Behavioral
have
profound
impact
well-being
but
especially
women
people
non-Caucasian
ethnicityMany
poorly
responsive
dopaminergic
due
degeneration
cholinergic,
noradrenergic,
serotoninergic
neurotransmitter
systemsAdjustments
needed
presence
impulsive
compulsive
behaviors
psychosis
acute
withdrawal
medications
almost
invariably
associated
worsening
increased
disabilityMedications
targeting
non-dopaminergic
systems
(serotonin,
noradrenaline)
may
improve
affective
symptomsA
thorough
neuropsychological
assessment
clinically
significant
should
always
be
considered
detect
features
supportive
impairmentEducation
well
involvement
an
team
warrantedDeclaration
interestA
Antonini
has
received
compensation
consultancy
speaker-related
activities
UCB,
Britannia,
AbbVie,
Zambon,
Bial,
Ever
Pharma,
Ferrer,
Theravance
Biopharma,
Bayer,
TreeFrog
Therapeutics,
Oligy,
Medscape.
He
receives
research
support
Horizon2020
Grant
825785,
101016902,
Ministry
Education
University
Research
(MIUR)
ARS01_01081,
Cariparo
Foundation.The
authors
no
other
relevant
affiliations
financial
any
organization
entity
interest
conflict
subject
matter
materials
discussed
manuscript
apart
disclosed.Reviewer
disclosuresPeer
reviewers
this
relationships
disclose.Additional
informationFundingThis
paper
was
not
funded.
Journal of Parkinson s Disease,
Journal Year:
2024,
Volume and Issue:
14(7), P. 1527 - 1530
Published: Sept. 10, 2024
Our
language
affects
patients'
perceptions
of
therapies.
In
Parkinson's
disease,
emergent
response
fluctuations
and
dyskinesias
typically
trigger
conversations
around
commencing
an
"Advanced
Therapy"
which
carries
notions
Advanced
Disease.
The
patient,
resolute
in
their
commitment
to
fighting
the
is
misled.
Chasing
reassurance
that
disease
has
not
yet
progressed
considerably;
they
may
therefore
resist
a
potentially
life-changing
therapy.
Instead,
we
should
offer
"Smart
Therapy".
This
term
more
accurately
positively
describes
therapies
on
stabilize
improve
quality
life,
without
focus
negative
connotations
progression
advanced
disease.
Current Opinion in Anaesthesiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 20, 2024
The
use
of
implantable
medical
devices
(IMDs)
continues
to
increase
with
estimates
that
10%
the
American
population
will
have
an
IMD
in
their
lifetime.
IMDs
require
special
considerations
for
management
perioperative
period
ensure
optimal
patient
care
and
safety.
This
review
summarizes
current
IMDs.
